607
Views
5
CrossRef citations to date
0
Altmetric
Cardiology: Editorial

Therapeutic options for statin-intolerant patients

, , &
Pages 345-349 | Accepted 11 Jan 2012, Published online: 31 Jan 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Miao Hu & Brian Tomlinson. (2014) Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opinion on Drug Metabolism & Toxicology 10:1, pages 51-65.
Read now
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Current Medical Research and Opinion 28:9, pages 1415-1419.
Read now

Articles from other publishers (3)

Michael S. Kostapanos, Matilda Florentin & Moses S. Elisaf. (2013) Fenofibrate and the kidney: an overview. European Journal of Clinical Investigation 43:5, pages 522-531.
Crossref
Michael S Kostapanos, Dimitri P Mikhailidis & Moses S Elisaf. (2012) Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. Future Cardiology 8:6, pages 813-817.
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Ezetimibe – a new approach in hypercholesterolemia management. Pharmacological Reports 64:4, pages 997-998.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.